Stockreport

Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results

Quince Therapeutics, Inc.  (QNCX) 
PDF Phase 3 NEAT clinical trial exceeds 50% enrollment with new study site activations expected to accelerate screenings and randomizationExisting cash position of $40.8 mil [Read more]